Upstream Bio Shares Dip 0.71% Amid Steady Revenue, Poised for Late-Stage Growth
Upstream Bio (UPB) trades near $2.73, reports steady revenue amid rising research costs, maintains robust cash flow, and plans future funding to advance late‑stage clinical candidates.
- UPSTREAM BIO INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read